Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case–time control study and a nested case-control study based on the French national health insurance (SNDS) cohort

Pauline Berthe,Guillaume Coiffier,Delphine Staumont,Pierre Guéret,Lucie-Marie Scailteux,Emmanuel Oger,Alain Dupuy,Alain Lescoat,Catherine Droitcourt

doi:10.1136/bmjopen-2021-059979

Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case–time control study and a nested case-control study based on the French national health insurance (SNDS) cohort

Pauline Berthe, Guillaume Coiffier + Show 7 more

Open Access

https://doi.org/10.1136/bmjopen-2021-059979

Copy DOI

Journal: BMJ open	Publication Date: Sep 1, 2022
Citations: 3	License type: open-access

Affiliation: Centre Hospitalier Universitaire de Rennes, Liver, Metabolisms and Cancer, Inserm, Institut de Recherche en Santé, Environnement et Travail, École des Hautes Études en Santé Publique, University of Rennes

#Risk Of Venous Thromboembolic Events #French National Health Insurance System + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionAtopic dermatitis (AD) is a highly prevalent, chronic, inflammatory skin disease. Several orally administered Janus kinase inhibitors (JAKis, including baricitinib, upadacitinib and abrocitinib) have received a marketing authorisation for AD.Clinical...

Full Text